Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$106.89
$113.77
$89.67
$121.64
$185.47B0.745.33 million shs3.11 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$724.87
-1.0%
$762.75
$370.68
$800.78
$695.71B0.342.30 million shs2.60 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$130.71
+2.9%
$126.34
$99.14
$133.10
$321.69B0.386.38 million shs12.75 million shs
Novartis AG stock logo
NVS
Novartis
$99.06
+0.7%
$97.92
$92.19
$108.78
$201.03B0.541.78 million shs2.34 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.26
-3.8%
$27.01
$25.23
$40.37
$148.75B0.6133.76 million shs47.04 million shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.00%+1.54%-4.14%-4.57%-1.71%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-1.00%-2.83%-6.49%+13.40%+92.65%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
+2.91%+4.42%+4.12%+8.19%+15.23%
Novartis AG stock logo
NVS
Novartis
+0.72%+7.01%+3.99%-7.56%-3.39%
Pfizer Inc. stock logo
PFE
Pfizer
-3.81%-0.49%-8.45%-8.03%-34.61%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Abbott Laboratories stock logo
ABT
Abbott Laboratories
4.9927 of 5 stars
3.35.04.24.52.52.52.5
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.765 of 5 stars
2.43.02.54.02.52.53.1
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
4.6633 of 5 stars
2.33.03.34.13.22.51.9
Novartis AG stock logo
NVS
Novartis
3.0932 of 5 stars
2.05.02.50.02.50.02.5
Pfizer Inc. stock logo
PFE
Pfizer
4.9782 of 5 stars
3.23.04.24.83.11.73.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abbott Laboratories stock logo
ABT
Abbott Laboratories
2.67
Moderate Buy$121.5013.67% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.84
Moderate Buy$728.050.44% Upside
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.58
Moderate Buy$131.250.41% Upside
Novartis AG stock logo
NVS
Novartis
2.25
Hold$115.0016.09% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.38
Hold$36.3343.84% Upside

Current Analyst Ratings

Latest MRK, PFE, NVS, ABT, and LLY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/24/2024
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$124.00
4/24/2024
Novartis AG stock logo
NVS
Novartis
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Perform ➝ Market Perform$114.00 ➝ $116.00
4/22/2024
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$141.00 ➝ $140.00
4/18/2024
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$128.00 ➝ $125.00
4/18/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$135.00
4/15/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$815.00
4/15/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
4/11/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$650.00 ➝ $723.00
4/8/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$140.00 ➝ $143.00
4/5/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$135.00
4/4/2024
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$120.00 ➝ $125.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$40.11B4.62$6.32 per share16.91$22.36 per share4.78
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$34.12B20.18$7.41 per share97.78$11.44 per share63.36
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$60.12B5.51$3.13 per share41.71$14.85 per share8.80
Novartis AG stock logo
NVS
Novartis
$45.44B4.46$11.32 per share8.75$22.87 per share4.33
Pfizer Inc. stock logo
PFE
Pfizer
$58.50B2.45$2.86 per share8.84$15.81 per share1.60

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$5.72B$3.2133.3020.882.5913.96%20.32%10.59%7/18/2024 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.24B$5.80124.9839.181.6315.36%51.22%9.94%4/30/2024 (Confirmed)
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$365M$0.14933.6413.221.650.61%9.33%3.61%5/28/2024 (Estimated)
Novartis AG stock logo
NVS
Novartis
$14.85B$7.4113.3712.481.5831.33%31.12%13.16%7/16/2024 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$2.12B$0.3670.179.121.193.62%10.88%4.91%5/1/2024 (Confirmed)

Latest MRK, PFE, NVS, ABT, and LLY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2024N/A
Pfizer Inc. stock logo
PFE
Pfizer
$0.57N/A-$0.57N/AN/AN/A  
4/30/2024N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$2.61N/A-$2.61N/AN/AN/A  
4/17/2024Q1 24
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$0.96$0.98+$0.02$1.26$9.88 billion$9.96 billion    
2/6/202412/31/2023
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$2.30$2.49+$0.19$2.56$8.95 billion$9.35 billion    
2/1/2024Q4 2023
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-$0.09$0.03+$0.12$0.54$14.49 billion$14.63 billion    
1/30/202412/31/2023
Novartis AG stock logo
NVS
Novartis
$1.64$1.53-$0.11-$1.08$11.69 billion$11.42 billion    
1/30/202412/31/2023
Pfizer Inc. stock logo
PFE
Pfizer
-$0.19$0.10+$0.29$0.80$14.37 billion$14.25 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$2.202.06%+12.31%68.54%53 Years
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.200.72%+15.15%89.66%10 Years
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.082.36%+6.08%2,200.00%13 Years
Novartis AG stock logo
NVS
Novartis
$2.432.45%+4.26%32.79%4 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.686.65%+2.57%466.67%15 Years

Latest MRK, PFE, NVS, ABT, and LLY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/24/2024
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.426.4%5/9/20245/10/20246/14/2024
2/16/2024
Abbott Laboratories stock logo
ABT
Abbott Laboratories
quarterly$0.551.9%4/12/20244/15/20245/15/2024
3/1/2024
Novartis AG stock logo
NVS
Novartis
annual$3.77723.1%3/7/20243/8/20243/7/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.35
1.64
1.16
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.69
0.94
0.73
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.89
1.25
1.00
Novartis AG stock logo
NVS
Novartis
0.39
1.15
0.93
Pfizer Inc. stock logo
PFE
Pfizer
0.69
0.91
0.69

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
75.18%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%
Novartis AG stock logo
NVS
Novartis
13.12%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
1.10%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.09%
Novartis AG stock logo
NVS
Novartis
0.01%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Abbott Laboratories stock logo
ABT
Abbott Laboratories
114,0001.74 billion1.72 billionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
43,000950.16 million948.93 millionOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
72,0002.53 billion2.53 billionOptionable
Novartis AG stock logo
NVS
Novartis
76,0572.04 billion2.04 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
88,0005.66 billion5.66 billionOptionable

NVS, PFE, MRK, ABT, and LLY Headlines

SourceHeadline
Want $2,000 in Annual Dividends? Invest $30,000 in These 3 StocksWant $2,000 in Annual Dividends? Invest $30,000 in These 3 Stocks
fool.com - April 26 at 7:45 AM
Pfizer Gets FDA OK For Beqvez Gene Therapy for Hemophilia BPfizer Gets FDA OK For Beqvez Gene Therapy for Hemophilia B
marketwatch.com - April 26 at 7:33 AM
Pfizers Beqvez Receives FDA Approval For Treatment Of Adults With Hemophilia BPfizer's Beqvez Receives FDA Approval For Treatment Of Adults With Hemophilia B
markets.businessinsider.com - April 26 at 7:33 AM
US FDA approves Pfizers gene therapy for rare bleeding disorderUS FDA approves Pfizer's gene therapy for rare bleeding disorder
reuters.com - April 26 at 7:33 AM
U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia BU.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B
finance.yahoo.com - April 26 at 7:33 AM
Pfizer Now Rivals The Worlds Most Expensive Medicine After FDA Approves Gene TherapyPfizer Now Rivals The World's Most Expensive Medicine After FDA Approves Gene Therapy
finance.yahoo.com - April 26 at 7:33 AM
UPDATE 2-US FDA approves Pfizers gene therapy for rare bleeding disorderUPDATE 2-US FDA approves Pfizer's gene therapy for rare bleeding disorder
finance.yahoo.com - April 26 at 7:33 AM
FDA approves Pfizers first gene therapy for rare inherited bleeding disorderFDA approves Pfizer's first gene therapy for rare inherited bleeding disorder
cnbc.com - April 26 at 7:02 AM
U.S. FDA Approves Pfizers BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia BU.S. FDA Approves Pfizer's BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B
businesswire.com - April 26 at 6:45 AM
Pfizer (NYSE:PFE) Trading Down 2.5%Pfizer (NYSE:PFE) Trading Down 2.5%
marketbeat.com - April 25 at 6:18 PM
Syon Capital LLC Boosts Stock Position in Pfizer Inc. (NYSE:PFE)Syon Capital LLC Boosts Stock Position in Pfizer Inc. (NYSE:PFE)
marketbeat.com - April 25 at 5:33 PM
3 Bargain Stocks Near 52-week Lows3 Bargain Stocks Near 52-week Lows
marketbeat.com - April 25 at 9:46 AM
3 Bargain Stocks Near 52-week Lows (PFE)3 Bargain Stocks Near 52-week Lows (PFE)
marketbeat.com - April 25 at 9:46 AM
GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technologyGlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
reuters.com - April 25 at 9:40 AM
UPDATE 1-Ad group WPP reports 1.6% drop in first-quarter organic growthUPDATE 1-Ad group WPP reports 1.6% drop in first-quarter organic growth
finance.yahoo.com - April 25 at 8:58 AM
Pfizer declares $0.42 dividendPfizer declares $0.42 dividend
msn.com - April 24 at 8:10 PM
Pfizer Inc. (NYSE:PFE) Shares Sold by Alaska Permanent Fund CorpPfizer Inc. (NYSE:PFE) Shares Sold by Alaska Permanent Fund Corp
marketbeat.com - April 24 at 5:28 PM
Pfizer Inc. (NYSE:PFE) to Issue Quarterly Dividend of $0.42Pfizer Inc. (NYSE:PFE) to Issue Quarterly Dividend of $0.42
marketbeat.com - April 24 at 5:22 PM
Pfizer Declares Second-Quarter 2024 DividendPfizer Declares Second-Quarter 2024 Dividend
businesswire.com - April 24 at 4:37 PM
Pfizer (NYSE:PFE) Trading Down 0.5%Pfizer (NYSE:PFE) Trading Down 0.5%
marketbeat.com - April 24 at 4:22 PM
Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?
zacks.com - April 24 at 1:06 PM
Analysts Estimate Pfizer (PFE) to Report a Decline in Earnings: What to Look Out forAnalysts Estimate Pfizer (PFE) to Report a Decline in Earnings: What to Look Out for
zacks.com - April 24 at 11:06 AM
Pfizer gets grant for treatment of cancer using engineered immune cells targeting bcmaPfizer gets grant for treatment of cancer using engineered immune cells targeting bcma
pharmaceutical-technology.com - April 24 at 10:09 AM
6 of the Highest-Yielding S&P 500 Stocks Offer Huge Passive Income6 of the Highest-Yielding S&P 500 Stocks Offer Huge Passive Income
247wallst.com - April 24 at 7:30 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Abbott Laboratories logo

Abbott Laboratories

NYSE:ABT
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Eli Lilly and Company logo

Eli Lilly and Company

NYSE:LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Merck & Co., Inc. logo

Merck & Co., Inc.

NYSE:MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Novartis logo

Novartis

NYSE:NVS
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Pfizer logo

Pfizer

NYSE:PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.